## Local Coverage Determination (LCD) for Rituximab (Rituxan®) (L29271)

### Contractor Information

<table>
<thead>
<tr>
<th>Contractor Name</th>
<th>Contractor Number</th>
<th>Contractor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Coast Service Options, Inc.</td>
<td>09102</td>
<td>MAC - Part B</td>
</tr>
</tbody>
</table>

### LCD Information

#### Document Information

<table>
<thead>
<tr>
<th>LCD ID Number</th>
<th>Primary Geographic Jurisdiction</th>
</tr>
</thead>
<tbody>
<tr>
<td>L29271</td>
<td>Florida</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LCD Title</th>
<th>Oversight Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab (Rituxan®)</td>
<td>Region IV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contractor's Determination Number</th>
<th>Original Determination Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9310</td>
<td>For services performed on or after 02/02/2009</td>
</tr>
</tbody>
</table>

#### AMA CPT/ADA CDT Copyright Statement

CPT codes, descriptions and other data only are copyright 2011 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. © 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply.

<table>
<thead>
<tr>
<th>Original Determination Ending Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>For services performed on or after 04/19/2011</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revision Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>For services performed on or after 04/19/2011</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revision Ending Date</th>
</tr>
</thead>
</table>

### CMS National Coverage Policy

Language quoted from CMS National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals are italicized throughout the Local Coverage Determination (LCD). NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See §1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

- CMS Manual System, Pub. 100-02, Medicare Benefit Policy, Chapter 15, Section 50
- CMS Manual System, Pub. 100-04, Medicare Claims Processing Manual, Chapter 17, Section 40
- CMS Manual System, Pub. 100-08, Medicare Program Integrity, Chapter 13, Section 13.1.3
- Social Security Act Section 1861 (t) (2) (b)

### Indications and Limitations of Coverage and/or Medical Necessity

**Rituximab (Rituxan®)–J9310**

Rituxan (Rituxan®) is a monoclonal antibody that targets a specific protein, known as CD20, on the surface of immune cells known as B-cells. Rituxan binds to CD20 and is believed to work with the body’s own immune system to attack and kill the marked B-cells.

Rituximab is FDA approved for the treatment of the following indications:
Non-Hodgkins Lymphoma (NHL)

· Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.

· Patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell, NHL as a single agent.

· Previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP or other anthracycline-based chemotherapy regimens.

· Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent after first-line treatment with CVP chemotherapy.

Rheumatoid Arthritis (RA)

· In combination with methotrexate to reduce signs and symptoms and to slow the progression of structural damage in adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Chronic Lymphocytic Leukemia (CLL)

• In combination with fludarabine and cyclophosphamide (Fc), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.

Wegener’s Granulomatosis and Microscopic Polyangiitis

• In combination with glucocorticoids, for the treatment of adult patients with Wegener’s Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

Medicare will consider the use of Rituximab as medically reasonable and necessary for the FDA approved uses as well as the following off-labeled indications:

· Low grade or follicular CD20-positive, B-cell non-Hodgkin’s lymphomas (re-induction treatment appropriate for responders and patients with stable disease)

· Intermediate and high grade NHL when used as a single agent, in combination with a CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) chemotherapy regimen, or in combination with other agents active in the disease

· Immune or idiopathic thrombocytopenia purpura

· Evans’ syndrome

· Waldenstrom’s Macroglobulinemia

· For the treatment of refractory thrombotic thrombocytopenic purpura (TTP) for patients who do not respond to plasmapheresis.

· Autoimmune hemolytic anemia

- Rituximab is covered for those patients with autoimmune hemolytic anemia condition that is refractory to conventional treatment (e.g., corticosteroid treatment and splenectomy).
Coding Information

Bill Type Codes:
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

Revenue Codes:
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

| 99999 | Not Applicable |

CPT/HCPCS Codes
GroupName
| J9310 | INJECTION, RITUXIMAB, 100 MG |

ICD-9 Codes that Support Medical Necessity

| 200.00 - 200.88 | RETICULOSARCOMA UNSPECIFIED SITE - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES |
| 202.00 - 202.98 | NODULAR LYMPHOMA UNSPECIFIED SITE - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF MULTIPLE SITES |
| 204.10 - 204.12 | CHRONIC LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION - CHRONIC LYMPHOID LEUKEMIA, IN RELAPSE |
| 273.3 | MACROGLOBULINEMIA |
| 283.0 | AUTOIMMUNE HEMOLYTIC ANEMIAS |
| 287.31 | IMMUNE THROMBOCYTOPENIC PURPURA |
| 287.32 | EVANS' SYNDROME |
| 446.0 | POLYARTERITIS NODOSA |
| 446.4 | WEGENER'S GRANULOMATOSIS |
| 446.6 | THROMBOTIC MICROANGIOPATHY |
| 714.0 | RHEUMATOID ARTHRITIS |
| 714.1 | FELTY'S SYNDROME |
| 714.2 | OTHER RHEUMATOID ARTHRITIS WITH VISCERAL OR SYSTEMIC INVOLVEMENT |

Diagnoses that Support Medical Necessity
See ICD-9 Codes that Support Medical Necessity

ICD-9 Codes that DO NOT Support Medical Necessity
All other diagnosis codes not listed as covered in the “ICD-9 Codes that Support Medical Necessity” section of this LCD.

| XX000 | Not Applicable |

ICD-9 Codes that DO NOT Support Medical Necessity Asterisk Explanation

Diagnoses that DO NOT Support Medical Necessity
All other diagnoses not listed as covered in the “ICD-9 Codes that Support Medical Necessity” section of this LCD.

Back to Top

General Information

Documentations Requirements
Medical record documentation maintained by the ordering/referring physician must substantiate the medical need for the use of these chemotherapy drugs by clearly indicating the condition for which these drugs are being used. This might include the type of cancer, staging, if applicable, prior therapy and the patient’s response to that therapy. This documentation is usually found in the history and physical or in the office/progress notes.

If the provider of the service is other than the ordering/referring physician, that provider must maintain copies of the ordering/referring physician’s order for the chemotherapy drug. The physician must state the clinical indication/medical need for using the chemotherapy drug in the order.

For patients receiving Rituximab, an explanation of lymphoma type and previous treatment(s) should be maintained in the patient’s medical record.

For the off-label indication of autoimmune hemolytic anemia, in addition to the above documentation requirements, the following documentation must be supported in the medical record: Hgb and Hct, reticulocyte count, bilirubin, hepatoglobulin, indirect and direct hepatoglobulintests), patients subjective complaints.

Appendices

Utilization Guidelines It is expected that these services would be performed as indicated by current medical literature and/or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity.

Dosage for the off label indication of autoimmune hemolytic anemia is as follows: 375 mg/m2 once weekly for four consecutive weeks.

See the Food and Drug Administration (FDA) drug label for recommended dosages for specific FDA indications.

Rituximab (Rituxan®) is supplied as a 100mg/10mL and 500mg/50mL solution in a single-use vial.

Sources of Information and Basis for Decision


U.S. Food and Drug Administration, Department of Health and Human Services, CDER web site updates, January 2008.

U.S. Food and Drug Administration, Department of Health and Human Services, CDER web site updates, January 2011.

U.S. Food and Drug Administration, Department of Health and Human Services, FDA News Release, April 19, 2011.


**Advisory Committee Meeting Notes** This Local Coverage Determination (LCD) does not reflect the sole opinion of the contractor or Contractor Medical Director. Although the final decision rests with the contractor, this LCD was developed in cooperation with advisory groups, which includes representatives from numerous societies.

**Start Date of Comment Period**

**End Date of Comment Period**

**Start Date of Notice Period** 05/01/2011

**Revision History Number** 3

**Revision History Explanation** Revision Number: 3
Start Date of Comment Period: N/A
Start Date of Notice Period: 07/01/2011
Revised Effective Date: 04/19/2011

LCR B2011-061
June 2011 Connection

Explanation of Revision: Under the “Indications and Limitations of Coverage and/or Medical Necessity” section of the LCD for FDA approved indications, added indications for Wegener’s Granulomatosis and Microscopic Polyangiitis. Under the “ICD-9 Codes that Support Medical Necessity” section of the LCD, added diagnosis codes 446.0 and 446.4. In addition, the “Sources of Information and Basis for Decision” section was updated. The effective date of this revision is for dates of service on or after April 19, 2011 for claims processed on or after 06/20/2011.

Revision Number: 2
Start Date of Comment Period: N/A
Start Date of Notice Period: 05/01/2011

Revised Effective Date 01/28/2011

LCR B2011-047
April 2011 Update

Explanation of Revision: Revised under the “Indications and Limitations of Coverage and/or Medical Necessity” section of the LCD, added additional FDA approval indication for follicular CD20-positive, B-cell NHL. In addition, updated the “Sources of Information and Basis for Decision” section of the LCD. Revision will be effective for dates of service on or after 01/28/2011 for claims processed on or after 03/31/2011.

Revision Number 1
Start Date of Comment Period: N/A
Start Date of Notice Period: 05/01/2010
Revised Effective Date 02/18/2010

LCR B2010-035
April 2010 Update

Explanation of Revision: Revised indications and limitations to add CLL as an FDA approved indication and removed CLL from the covered off-label list. Revisions will be effective for dates of services on or after 02/18/2010 for claims processed on or after 04/06/2010.

Revision Number: Original
Start Date of Comment Period: N/A
Start Date of Notice Period: 12/04/2008
Revised Effective Date 02/02/2009

LCR B2009-044FL
LCR B2009-045PR/VI
December 2008 Bulletin

This LCD consolidates and replaces all previous policies and publications on this subject by the carrier predecessors of First Coast Service Options, Inc. (Triple S and FCSO).

For Florida (00590) this LCD (L29271) replaces LCD L25077 as the policy in notice. This document (L29271) is effective on 02/02/2009.

Reason for Change

Related Documents
This LCD has no Related Documents.

LCD Attachments
There are no attachments for this LCD.

Back to Top

All Versions
Updated on 06/15/2011 with effective dates 04/19/2011 - N/A
Updated on 04/01/2011 with effective dates 01/28/2011 - 04/18/2011
Updated on 04/06/2010 with effective dates 02/18/2010 - 01/27/2011
Updated on 11/30/2008 with effective dates 02/02/2009 - N/A
Read the LCD Disclaimer
Back to Top